Search results for "OPD"

showing 10 items of 506 documents

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct

What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?

2013

<b><i>Background and Objective:</i></b> We aimed to explore to what extent an unselected population of chronic obstructive pulmonary disease (COPD) outpatients would be eligible for inclusion in randomized clinical trials (RCTs). <b><i>Methods:</i></b> Retrospective analysis of the clinical records of outpatient subjects with an ascertained diagnosis of COPD. COPD outpatients were assessed against the following inclusion criteria: 40 < age < 80 years, current or former smokers, forced expiratory volume in the first second (FEV<sub>1</sub>) <70% predicted, no long-term oxygen therapy, no other concomitant lung diseases and …

AdultLung DiseasesMalePulmonary and Respiratory Medicinemedicine.medical_specialtyMEDLINEPulmonary diseaseComorbiditySettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionCohort StudiesPulmonary Disease Chronic ObstructiveRandomized controlled triallawForced Expiratory VolumeInternal medicinePragmatic Clinical Trials as TopicmedicineHumansCOPDAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overCOPDbusiness.industryPatient SelectionSmokingAge FactorsOxygen Inhalation TherapyRetrospective cohort studyMiddle Agedmedicine.diseaseComorbidityBronchiectasisrespiratory tract diseasesPhysical therapyFemaleObservational studyCognition DisordersbusinessCohort study
researchProduct

The difference in risk of chronic pulmonary disease morbidity and mortality between former elite athletes and ordinary men in Finland.

2019

The impact of a history of competitive sports on later smoking behaviour and occurrence of chronic pulmonary diseases is poorly known. We investigated how a history of elite level sports predicted later pulmonary disease morbidity and mortality. Chronic pulmonary disease incidence was assessed from national hospital and cause-of-death registers from 1970 to 2015 among Finnish male former elite athletes (n = 2078) and matched controls (n = 1453) alive in 1970 (mean age 45.0 years). Hazard ratios (HRs) were calculated by Cox proportional hazards model. In 1985, cohort members reported on their smoking habits, engagement in physical activity/sports and physician-diagnosed chronic diseases. The…

AdultLung DiseasesMalemedicine.medical_specialtyChronic bronchitisCompetitive Behavior030209 endocrinology & metabolismPhysical Therapy Sports Therapy and RehabilitationComorbidity03 medical and health sciences0302 clinical medicineAge DistributionRisk FactorsInternal medicineCause of DeathmedicineHumansOrthopedics and Sports MedicineLongitudinal StudiesYoung adultExerciseFinlandProportional Hazards ModelsCOPDbiologyAthletesProportional hazards modelbusiness.industryHazard ratioSmoking030229 sport sciencesGeneral MedicineLength of StayMiddle Agedbiology.organism_classificationmedicine.disease3. Good healthSocioeconomic FactorsAthletesCohortChronic DiseasePhysical EndurancebusinessCohort studyEuropean journal of sport science
researchProduct

Assessment of Analysis of Urinary Pneumococcal Antigen by Immunochromatography for Etiologic Diagnosis of Community-Acquired Pneumonia in Adults

2006

ABSTRACT The limitations of conventional microbiologic methods (CMM) for etiologic diagnosis of community pneumococcal pneumonia have made faster diagnostic techniques necessary. Our aim was to evaluate the usefulness of the immunochromatography (ICT) technique for detecting urinary Streptococcus pneumoniae antigen in the etiologic diagnosis of community-acquired pneumonias (CAP). This was a prospective study on in-patients with CAP in a tertiary hospital conducted from October 2000 to March 2004. Apart from using CMM to reach an etiologic diagnosis, we determined pneumococcal antigen in concentrated urine by ICT. We also determined the urinary pneumococcal antigen (UPA) content in patients…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAdolescentClinical BiochemistryImmunologymedicine.disease_causeCommunity-acquired pneumoniaInternal medicineStreptococcus pneumoniaemedicineHumansImmunology and AllergyProspective StudiesAgedAged 80 and overAntigens BacterialChromatographyCOPDbusiness.industryClinical and Diagnostic Laboratory ImmunologyRespiratory infectionMiddle AgedPneumonia Pneumococcalmedicine.diseaseCommunity-Acquired InfectionsPneumoniaPneumococcal infectionsStreptococcus pneumoniaePneumococcal pneumoniaImmunologyImmunologic TechniquesEtiologyFemalebusinessClinical and Vaccine Immunology
researchProduct

Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease

2014

Chronic obstructive pulmonary disease (COPD) and lung cancer are widespread lung diseases. Cigarette smoking is a high risk factor for both the diseases. COPD may increase the risk of developing lung cancer. Thus, it is crucial to be able to distinguish between these two pathological states, especially considering the early stages of lung cancer. Novel diagnostic and monitoring tools are required to properly determine lung cancer progression because this information directly impacts the type of the treatment prescribed. In this study, serum samples collected from 22 COPD and 77 lung cancer (TNM stages I, II, III, and IV) patients were analyzed. Then, a collection of NMR metabolic fingerprin…

AdultMaleOncologymedicine.medical_specialtyLung NeoplasmsMagnetic Resonance SpectroscopyClinical BiochemistryPharmaceutical ScienceCreatineAnalytical ChemistryDiagnosis DifferentialPulmonary Disease Chronic Obstructivechemistry.chemical_compoundPredictive Value of TestsCarcinoma Non-Small-Cell LungInternal medicineDrug DiscoveryBiomarkers TumormedicineHumansMetabolomicsLeast-Squares AnalysisRisk factorLung cancerLungPathologicalEarly Detection of CancerSpectroscopyAgedNeoplasm StagingAged 80 and overUnivariate analysisCOPDLungChemistryDiscriminant AnalysisMiddle AgedPrognosismedicine.diseaserespiratory tract diseasesmedicine.anatomical_structureMultivariate AnalysisDisease ProgressionFemaleLung cancer stagingJournal of Pharmaceutical and Biomedical Analysis
researchProduct

Airway epithelial dysfunction and mesenchymal transition in chronic obstructive pulmonary disease: Role of Oct-4

2021

Abstract The airway epithelium is a dynamic tissue that undergoes slow but constant renewal. Dysregulation of airway epithelial function related to cigarette smoke exposure plays an important role in the pathophysiology of COPD. Oct4 is a transcription factor responsible for maintaining cellular self-renewal and regeneration, and CD146 and CD105/Endoglin are adhesion molecules involved in cell proliferation, differentiation, epithelial-mesenchymal-transition and tissue remodeling. Bronchial biopsy specimens (BBs) were obtained from 7 healthy controls (HC) and 10 COPD and subjected to paraffin embedding; BBs from HC were also used for epithelial cell expansion and pHBEC/ALI (air-liquid inter…

AdultMalePathologymedicine.medical_specialtyEMT (epithelial-mesenchymal transition)Epithelial-Mesenchymal TransitionRespiratory SystemOct-4CD146 AntigenGeneral Biochemistry Genetics and Molecular BiologyCigarette SmokingPulmonary Disease Chronic ObstructiveAirway epithelium de-differentiationHumansMedicineGeneral Pharmacology Toxicology and PharmaceuticsAgedCOPDbusiness.industryCell adhesion moleculeMesenchymal stem cellEndoglinCell DifferentiationGeneral MedicineMiddle AgedEndoglinmedicine.diseaseCigarette smoke exposureEpitheliumrespiratory tract diseasesCD105medicine.anatomical_structureCD146Case-Control StudiesImmunohistochemistryRespiratory epitheliumCD146FemalebusinessOctamer Transcription Factor-3Life Sciences
researchProduct

Extracellular matrix composition in COPD

2012

Extracellular matrix (ECM) composition has an important role in determining airway structure. We postulated that ECM lung composition of chronic obstructive pulmonary disease (COPD) patients differs from that observed in smoking and nonsmoking subjects without airflow obstruction. We determined the fractional areas of elastic fibres, type-I, -III and -IV collagen, versican, decorin, biglycan, lumican, fibronectin and tenascin in different compartments of the large and small airways and lung parenchyma in 26 COPD patients, 26 smokers without COPD and 16 nonsmoking control subjects. The fractional area of elastic fibres was higher in non-obstructed smokers than in COPD and nonsmoking controls…

AdultMalePulmonary and Respiratory MedicineLumicanPathologymedicine.medical_specialtyDecorinLumicanTenascinSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic ObstructiveBiglycanParenchymamedicineHumansCOPDLungAgedCOPDLungbiologybusiness.industryBiglycanSmokingTenascinMiddle Agedrespiratory systemmedicine.diseaseImmunohistochemistryExtracellular MatrixFibronectinsRespiratory Function Testsrespiratory tract diseasesmedicine.anatomical_structureChondroitin Sulfate ProteoglycansKeratan SulfateCase-Control Studiesbiology.proteinVersicanFemaleCollagenDecorinbusiness
researchProduct

Airway neutrophilia in COPD is not associated with increased neutrophil survival

2006

Neutrophilic airway inflammation is a prominent feature of chronic obstructive pulmonary disease (COPD) and correlates with disease severity. The mechanisms that determine the extent of neutrophilia could involve increased influx or prolonged survival of neutrophils. The aim of the study was to assess whether neutrophil pro-survival mechanisms are increased in the airways of subjects with COPD owing to the presence of anti-apoptotic factors in the bronchial lining fluid. Induced sputum samples were collected from 20 subjects with stable COPD, 14 healthy smokers and 14 healthy controls. Quantification of apoptotic neutrophils was based on typical morphological cell changes. Anti-apoptotic, p…

AdultMalePulmonary and Respiratory MedicineNeutrophilsNeutrophileRespiratory SystemApoptosisInflammationGranulocyteNeutrophil ActivationPulmonary Disease Chronic ObstructiveForced Expiratory VolumeHumansMedicineAnnexin A5Cells CulturedAgedCOPDbusiness.industrySmokingRespiratory diseaseSputumMiddle AgedFlow Cytometrymedicine.diseaseNeutrophiliarespiratory tract diseasesmedicine.anatomical_structureCase-Control StudiesImmunologySputumFemalemedicine.symptomAirwaybusinessFollow-Up StudiesEuropean Respiratory Journal
researchProduct

18-yr cumulative incidence of respiratory/allergic symptoms/diseases and risk factors in the Pisa epidemiological study

2019

Abstract Background Few population-based studies on the effects of environmental exposure variation exist. Aim Assessing respiratory symptom/disease incidence related to risk factor exposure changes. Methods A longitudinal general population sample from two surveys (PISA2:1991–1993; PISA3:2009–2011; no. = 970), aged ≥20 years at baseline, completed a questionnaire on respiratory symptoms/diseases, risk factor exposure and performed spirometry. 18-year follow-up cumulative incidence of respiratory symptoms/diseases and longitudinal changes (persistence, incidence, remittance) in risk factor exposure were computed. Results Cumulative incidence values were: 3.2% (corresponding to a 1.8‰/year i…

AdultMalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyTime FactorsAllergyPopulationYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsSurveys and QuestionnairesInternal medicineWheezeTobaccomedicineCOPDHumansCumulative incidence030212 general & internal medicineeducationEnvironmental and occupational Health and EpidemiologyAgedAsthmaCOPDeducation.field_of_studymedicine.diagnostic_testbusiness.industryIncidence (epidemiology)SmokingEnvironmental ExposureEnvironmental exposureMiddle AgedRespiration Disordersmedicine.diseaseAsthmarespiratory tract diseases030228 respiratory systemAllergy; Asthma; COPD; Environmental & occupational health and epidemiology; TobaccoFemalemedicine.symptombusinessEnvironmental & occupational health and epidemiologyRespiratory Medicine
researchProduct

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

2014

Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β 2 -agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the effects of QVA149 on exercise tolerance, hyperinflation, lung function and lung volumes versus placebo and tiotropium. Methods Patients with moderate-to-severe COPD were randomized to QVA149 110/50 μg, placebo or tiotropium 18 μg once daily in a blinded, 3-period crossover study for 3 weeks. The primary endpoint was exercise endurance time at Day 21 for QVA149 versus placebo. R…

AdultMalePulmonary and Respiratory Medicinemedicine.drug_classVital CapacityScopolamine DerivativesHyperinflationQuinolonesPlaceboDrug Administration SchedulePulmonary Disease Chronic ObstructiveFunctional residual capacityDouble-Blind MethodForced Expiratory VolumeBronchodilatormedicineClinical endpointHumansLung volumesTiotropium BromideExerciseAgedCOPDCross-Over StudiesExercise Tolerancebusiness.industryChronic obstructive pulmonary diseaseTiotropiumQVA149Middle Agedmedicine.diseaseGlycopyrrolateCrossover studyBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeSpirometryAnesthesiaIndansIndacaterolFemaleLung Volume Measurementsbusinessmedicine.drugRespiratory Medicine
researchProduct